Poxel

ISIN: FR0012432516 | Ticker: POXEL

Sector: Health Care – Sub-Industry: Biotechnology

Country: France

About Poxel

Company Description

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterium-modified thiazolidinedione (dTZD) platforms targeting chronic and rare metabolic diseases. Poxel’s first-in-class lead product, TWYMEEG® (Imeglimin), that targets mitochondrial dysfunction, has been approved for the treatment of type 2 diabetes in Japan.

Year founded

2009

Served area

Worldwide

Headcount

Headquarters

Immeuble Le Sunway 259/261 Avenue Jean Jaurès, 69007 Lyon – France

Filings & Publications

Insider Trades

Capital markets information

ISIN

FR0012432516

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Paris

Main Stock Exchange

View Poxel on stock exchange

Contact Investor Relations department

First name*

Last name*

Your email*

Your phone number

Your company

Your message

I agree to the terms of the privacy policy.*

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.